Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells

Luzhna,Lidia; Golubov,Andrey; Ilnytskyy,Slava; Chekhun,Vasyl  F.; Kovalchuk,Olga

doi:10.3892/ijo.2013.1845

Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells

Authors:
- Lidia Luzhna
- Andrey Golubov
- Slava Ilnytskyy
- Vasyl F. Chekhun
- Olga Kovalchuk
View Affiliations

Affiliations: Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K3M4, Canada, Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences (NAS) of Ukraine, Kiev 03022, Ukraine
Published online on: March 4, 2013 https://doi.org/10.3892/ijo.2013.1845
Pages: 1692-1708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A positive response to breast cancer treatment is largely dependent on the successful combination of anticancer treatment modalities, such as chemotherapy and radiation therapy. Unfortunately, chemotherapy resistance occurs frequently. Furthermore, drug‑resistant tumors can become unresponsive to other antitumor therapies, and they often fail to respond to radiation therapy. The molecular structures underlying the radiation responses of chemoresistant cells and tumors are not well understood. We analyzed the effect of ionizing radiation on MCF-7 human breast adenocarcinoma cells and their doxorubicin‑resistant variant, MCF-7/DOX. The results demonstrated that drug‑resistant MCF-7/DOX cells were less susceptible to radiation-induced DNA damage and apoptosis. This was proven through gene expression profiling, lower levels of γH2AX foci upon irradiation, and altered levels of DNA repair proteins, including pATM, KU70 and RAD51. Additionally, MCF-7/DOX drug‑resistant cells harbored DNA polymerases with significantly low fidelity. In summary, our study revealed that drug-resistant MCF-7/DOX cells have high DNA repair potential and low-fidelity DNA polymerases, seemingly sacrificing specificity and efficiency to gain higher survival potential. In the long run, this may lead to an increased probability of mutation accumulation and further the development of an even more pronounced resistance phenotype. Therefore, this study provides a roadmap for the analysis of the roles of the DNA repair function and effectiveness, and apoptosis in response to radiation, chemotherapy and combinations of both treatment modalities.

View Figures

View References

1.	Guarneri V and Conte PF: The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 31(Suppl 1): S149–S161. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Lehnert M: Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 32A:912–920. 1996. View Article : Google Scholar : PubMed/NCBI
3.	Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Fojo T: Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 10:59–67. 2007. View Article : Google Scholar
5.	O’Driscoll L and Clynes M: Molecular markers of multiple drug resistance in breast cancer. Chemotherapy. 52:125–129. 2006.PubMed/NCBI
6.	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 23:2934–2949. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 65:95–106. 2000.PubMed/NCBI
9.	Karran P: Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 22:1931–1937. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Rixe O and Fojo T: Is cell death a critical end point for anti-cancer therapies or is cytostasis sufficient? Clin Cancer Res. 13:7280–7287. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer. 32A:921–926. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580:998–1009. 2006.PubMed/NCBI
13.	Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Petrelli A and Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 15:422–432. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP and Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther. 6:1089–1098. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Dean-Colomb W and Esteva FJ: Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 35:S31–S40. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Ozols RF, Masuda H and Hamilton TC: Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogr. 159–165. 1988.PubMed/NCBI
20.	Shimm DS, Olson S and Hill AB: Radiation resistance in a multidrug resistant human T-cell leukemia line. Int J Radiat Oncol Biol Phys. 15:931–936. 1988. View Article : Google Scholar : PubMed/NCBI
21.	Belli JA: Interaction between radiation and drug damage in mammalian cells. IV. Radiation response of adriamycin-resistant V79 cells. Radiat Res. 119:88–100. 1989. View Article : Google Scholar : PubMed/NCBI
22.	Lehnert S, Greene D and Batist G: Radiation response of drug-resistant variants of a human breast cancer cell line. Radiat Res. 118:568–580. 1989. View Article : Google Scholar : PubMed/NCBI
23.	Lehnert S, Greene D and Batist G: Radiation response of drug-resistant variants of a human breast cancer cell line: the effect of glutathione depletion. Radiat Res. 124:208–215. 1990. View Article : Google Scholar : PubMed/NCBI
24.	Alaoui-Jamali MA, Batist G and Lehnert S: Radiation-induced damage to DNA in drug- and radiation-resistant sublines of a human breast cancer cell line. Radiat Res. 129:37–42. 1992. View Article : Google Scholar : PubMed/NCBI
25.	Miller PR, Hill AB, Slovak ML and Shimm DS: Radiation resistance in a doxorubicin-resistant human fibrosarcoma cell line. Am J Clin Oncol. 15:216–221. 1992. View Article : Google Scholar : PubMed/NCBI
26.	Zhang Y, Sweet KM, Sognier MA and Belli JA: Interaction between radiation and drug damage in mammalian cells. VI. Radiation and doxorubicin age-response function of doxorubicin-sensitive and -resistant Chinese hamster cells. Radiat Res. 132:105–111. 1992. View Article : Google Scholar
27.	Lehnert S, Vestergaard J, Batist G and Aloui-Jamali MA: Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma. Radiat Res. 139:232–239. 1994. View Article : Google Scholar : PubMed/NCBI
28.	Liang K, Lu Y, Jin W, Ang KK, Milas L and Fan Z: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2:1113–1120. 2003.PubMed/NCBI
29.	Koukourakis MI, Koukouraki S, Giatromanolaki A, et al: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 17:3512–3521. 1999.PubMed/NCBI
30.	Gewirtz DA: Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat. 62:223–235. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Reinhold WC, Kouros-Mehr H, Kohn KW, et al: Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res. 63:1000–1011. 2003.
32.	Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
33.	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
34.	Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009.PubMed/NCBI
35.	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
36.	Tryndyak VP, Kovalchuk O and Pogribny IP: Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther. 5:65–70. 2006. View Article : Google Scholar
37.	Gening LV, Petrochenkov AN, Reshetnyak AB, Andreeva LE and Tarantul VZ: DNA polymerase iota-like activity in crude cell extracts of different mouse organs. Biochemistry (Mosc). 69:435–440. 2004. View Article : Google Scholar : PubMed/NCBI
38.	Olive PL and Banath JP: The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 1:23–29. 2006. View Article : Google Scholar : PubMed/NCBI
39.	Tice RR and Strauss GH: The single cell gel electrophoresis/comet assay: a potential tool for detecting radiation-induced DNA damage in humans. Stem Cells. 13(Suppl 1): 207–214. 1995.PubMed/NCBI
40.	Sedelnikova OA and Bonner WM: GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle. 5:2909–2913. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Carpenter AE, Jones TR, Lamprecht MR, et al: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7:R1002006. View Article : Google Scholar : PubMed/NCBI
42.	Lamprecht MR, Sabatini DM and Carpenter AE: CellProfiler: free, versatile software for automated biological image analysis. Biotechniques. 42:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Bebenek K and Kunkel TA: Functions of DNA polymerases. Adv Protein Chem. 69:137–165. 2004. View Article : Google Scholar
44.	Shcherbakova PV, Bebenek K and Kunkel TA: Functions of eukaryotic DNA polymerases. Sci Aging Knowledge Environ 2003. RE32003.PubMed/NCBI
45.	Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995. View Article : Google Scholar
46.	Little JB: Radiation carcinogenesis. Carcinogenesis. 21:397–404. 2000. View Article : Google Scholar
47.	Huang L, Snyder AR and Morgan WF: Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene. 22:5848–5854. 2003. View Article : Google Scholar : PubMed/NCBI
48.	Bonner WM, Redon CE, Dickey JS, et al: GammaH2AX and cancer. Nat Rev Cancer. 8:957–967. 2008. View Article : Google Scholar : PubMed/NCBI
49.	Olive PL: DNA damage and repair in individual cells: applications of the comet assay in radiobiology. Int J Radiat Biol. 75:395–405. 1999. View Article : Google Scholar : PubMed/NCBI
50.	West SC: Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 4:435–445. 2003. View Article : Google Scholar : PubMed/NCBI
51.	McGlynn P and Lloyd RG: Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol. 3:859–870. 2002. View Article : Google Scholar : PubMed/NCBI
52.	Helleday T: Pathways for mitotic homologous recombination in mammalian cells. Mutat Res. 532:103–115. 2003. View Article : Google Scholar : PubMed/NCBI
53.	Hoeijmakers JH: DNA repair mechanisms. Maturitas. 38:17–23. 2001. View Article : Google Scholar : PubMed/NCBI
54.	Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S and Lieberman J: gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell. 20:801–809. 2005. View Article : Google Scholar : PubMed/NCBI
55.	Lundin C, Schultz N, Arnaudeau C, Mohindra A, Hansen LT and Helleday T: RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. J Mol Biol. 328:521–535. 2003. View Article : Google Scholar : PubMed/NCBI
56.	Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 411:366–374. 2001. View Article : Google Scholar : PubMed/NCBI
57.	Jin S and Weaver DT: Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions. EMBO J. 16:6874–6885. 1997. View Article : Google Scholar : PubMed/NCBI
58.	Fornari FA, Randolph JK, Yalowich JC, Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 45:649–656. 1994.PubMed/NCBI
59.	Fortune JM and Osheroff N: Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 64:221–253. 2000. View Article : Google Scholar : PubMed/NCBI
60.	Khimani AH, Mhashilkar AM, Mikulskis A, et al: Housekeeping genes in cancer: normalization of array data. Biotechniques. 38:739–745. 2005. View Article : Google Scholar : PubMed/NCBI
61.	Rubie C, Kempf K, Hans J, et al: Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes. 19:101–109. 2005. View Article : Google Scholar : PubMed/NCBI
62.	Barnard GF, Staniunas RJ, Bao S, et al: Increased expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma. Cancer Res. 52:3067–3072. 1992.PubMed/NCBI
63.	Henry JL, Coggin DL and King CR: High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. Cancer Res. 53:1403–1408. 1993.PubMed/NCBI
64.	Lukyanova NY, Rusetskya NV, Tregubova NA and Chekhun VF: Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol. 31:87–91. 2009.PubMed/NCBI
65.	Gyorffy B, Serra V, Jurchott K, et al: Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene. 24:7542–7551. 2005. View Article : Google Scholar : PubMed/NCBI
66.	Huang J, Tan PH, Thiyagarajan J and Bay BH: Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol. 16:558–565. 2003. View Article : Google Scholar : PubMed/NCBI
67.	Saleh EM, El-Awady RA, Abdel Alim MA and Abdel Wahab AH: Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys. 55:95–105. 2009. View Article : Google Scholar
68.	Miyara H, Hida T, Nishida K, et al: Modification of chemoradiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene. Jpn J Clin Oncol. 26:1–5. 1996. View Article : Google Scholar : PubMed/NCBI
69.	Harper ME, Antoniou A, Villalobos-Menuey E, et al: Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 16:1550–1557. 2002. View Article : Google Scholar : PubMed/NCBI
70.	Diehn M, Cho RW, Lobo NA, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
71.	Kang JH, Song KH, Jeong KC, et al: Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer. 11:3342011. View Article : Google Scholar : PubMed/NCBI
72.	Mihich E: On the immunomodulating effects of anti-cancer drugs and their therapeutic exploitation. Jpn J Clin Oncol. 30:469–471. 2000. View Article : Google Scholar : PubMed/NCBI
73.	Ehrke MJ, Verstovsek S, Zaleskis G, et al: Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother. 42:221–230. 1996.PubMed/NCBI
74.	Cahill DP, Lengauer C, Yu J, et al: Mutations of mitotic checkpoint genes in human cancers. Nature. 392:300–303. 1998. View Article : Google Scholar : PubMed/NCBI
75.	Nguyen HG, Makitalo M, Yang D, Chinnappan D, St Hilaire C and Ravid K: Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 23:2741–2748. 2009. View Article : Google Scholar : PubMed/NCBI
76.	Sak A, Stuschke M, Groneberg M, Kubler D, Pottgen C and Eberhardt WE: Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys. 84:492–499. 2012. View Article : Google Scholar : PubMed/NCBI
77.	Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A and Hoffman B: Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 16:129–140. 2011. View Article : Google Scholar : PubMed/NCBI
78.	Kunkel TA and Burgers PM: Dividing the workload at a eukaryotic replication fork. Trends Cell Biol. 18:521–527. 2008. View Article : Google Scholar : PubMed/NCBI
79.	Matsuda T, van de Berg BJ, Bebenek K, Osheroff WP, Wilson SH and Kunkel TA: The base substitution fidelity of DNA polymerase beta-dependent single nucleotide base excision repair. J Biol Chem. 278:25947–25951. 2003. View Article : Google Scholar : PubMed/NCBI
80.	Kunkel TA, Pavlov YI and Bebenek K: Functions of human DNA polymerases eta, kappa and iota suggested by their properties, including fidelity with undamaged DNA templates. DNA Repair (Amst). 2:135–149. 2003. View Article : Google Scholar : PubMed/NCBI
81.	Beard WA, Shock DD, Vande Berg BJ and Wilson SH: Efficiency of correct nucleotide insertion governs DNA polymerase fidelity. J Biol Chem. 277:47393–47398. 2002. View Article : Google Scholar
82.	Goodman MF and Tippin B: Sloppier copier DNA polymerases involved in genome repair. Curr Opin Genet Dev. 10:162–168. 2000. View Article : Google Scholar : PubMed/NCBI
83.	Taylor ST, Hickman JA and Dive C: Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas. Endocr Relat Cancer. 6:21–23. 1999. View Article : Google Scholar : PubMed/NCBI
84.	Banath JP, Macphail SH and Olive PL: Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 64:7144–7149. 2004. View Article : Google Scholar : PubMed/NCBI
85.	Jeggo P and Lobrich M: Radiation-induced DNA damage responses. Radiat Prot Dosimetry. 122:124–127. 2006. View Article : Google Scholar : PubMed/NCBI
86.	Baumann P and West SC: Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 23:247–251. 1998. View Article : Google Scholar : PubMed/NCBI
87.	Dudas A and Chovanec M: DNA double-strand break repair by homologous recombination. Mutat Res. 566:131–167. 2004. View Article : Google Scholar : PubMed/NCBI
88.	Benson FE, Baumann P and West SC: Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature. 391:401–404. 1998. View Article : Google Scholar : PubMed/NCBI
89.	Goodarzi AA, Block WD and Lees-Miller SP: The role of ATM and ATR in DNA damage-induced cell cycle control. Prog Cell Cycle Res. 5:393–411. 2003.PubMed/NCBI
90.	Goodarzi AA, Jonnalagadda JC, Douglas P, et al: Auto-phosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 23:4451–4461. 2004. View Article : Google Scholar : PubMed/NCBI
91.	Alexander A, Cai SL, Kim J, et al: ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA. 107:4153–4158. 2010. View Article : Google Scholar : PubMed/NCBI
92.	Harris AL: DNA repair: relationship to drug and radiation resistance, metastasis and growth factors. Int J Radiat Biol Relat Stud Phys Chem Med. 48:675–690. 1985. View Article : Google Scholar : PubMed/NCBI